ERGIC1 Methylation Marker for Direct mMDSC Identification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods are inadequate for reliably and efficiently identifying and quantifying specific subpopulations of monocytic myeloid-derived suppressor cells (mMDSCs) without the need for purification or enrichment steps, particularly in complex biological samples.
Innovation Solution
An in vitro method analyzing the methylation status of specific CpG positions in the ERGIC1 gene region, specifically CpG positions 56, 62, 71, 121, 170, and 227, to identify CD15- mMDSCs, utilizing bisulfite conversion and PCR-based techniques to distinguish them from other immune cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional flow cytometry or immunophenotyping methods are used to identify mMDSCs, then cell surface markers can be detected, but these methods require complex sample preparation including purification and enrichment steps
Solution Approach 1:
The invention extracts and utilizes the unique epigenetic signature (specific DNA methylation pattern at ERGIC1 gene) that is inherent to mMDSCs, separating the identification capability from the need for physical cell purification. By targeting the methylated DNA sequence directly in crude lysates, the method extracts the diagnostic information without requiring complex sample preparation steps.
Solution Approach 2:
The invention introduces an intermediary approach by using DNA methylation status as a mediator between cell identity and detection. Instead of directly detecting cell surface proteins or morphology, the method uses the stable epigenetic mark as an intermediary that can be detected in crude samples, bridging the gap between complex cell identification and simple assay execution.
2Quantity of substance
If flow cytometry is used for mMDSC quantification, then cell population can be measured, but the method requires time-consuming purification and enrichment procedures
Solution Approach 1:
The invention performs preliminary action by targeting the stable DNA methylation mark that persists through cell lysis, eliminating the need for time-consuming cell purification and enrichment steps. The epigenetic signature is preserved in crude lysates, allowing direct quantification without intermediate processing steps that consume time.
Solution Approach 2:
The invention replaces the mechanical separation and enrichment processes of flow cytometry with a biochemical detection approach. Instead of physically separating cells based on surface markers, the method uses molecular recognition of the methylated DNA sequence, substituting mechanical complexity with biochemical specificity.
3Ease of operation
If epigenetic markers are used for cell identification, then purification steps can be avoided, but the detection of specific methylation patterns requires sophisticated methods
Solution Approach 1:
The invention segments the complex task of epigenetic detection by focusing on a specific, localized methylation pattern at the ERGIC1 gene rather than analyzing global methylation status. This segmentation allows the use of targeted approaches like MSP or qMSP that are simpler than whole-genome methylation analysis while maintaining the advantage of working with crude samples.
Solution Approach 2:
The invention changes the detection parameter from protein expression (flow cytometry) or global epigenetic profiling (complex sequencing) to a specific DNA methylation pattern at a defined genomic locus. This parameter change enables the use of established, relatively simple techniques like MSP that can detect methylation status in crude DNA samples without requiring sophisticated equipment or complex protocols.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables robust identification and quantification of CD15- mMDSCs in complex samples without purification, providing a reliable tool for clinical applications in immune cell analysis and disease diagnosis.
Implementation Method 1
utilizing bisulfite conversion and PCR-based techniques to distinguish them from other immune cells
Data Source
Figure 1
Figure 2
AI summary
The present invention relates to a method, in particular an in vitro method, for identifying specific immune cells, in particular MDSCs, comprising analyzing a modification, preferably the methylation status,of at least one CpG position in the mammalian gene region for endoplasmatic reticulum-golgi intermediate compartment 1 (ERGIC1), wherein a demethylation or lack of methylation or modification of said gene region is indicative for an MDSC, when compared to a non-MDSC. The analyses according to the invention can identify specific sub-populations of MDSCs, namely monocytic MDSCs (m MDSCs) on an epigenetic level and distinguish them from all other cells in complex samples, such as, for example, other blood or immune cells. The present invention furthermore provides an improved method for quantifying m MDSCs, in particular in complex samples. The method can be performed without a step of purifying and/or enriching cells, preferably in whole blood and/or non-trypsinized tissue.